Emerging evidence · Grade B
GHRP-2
GHRP-2 Acetate (Growth Hormone Releasing Peptide-2)
Score
66 / 100
Class
GH-releasing peptide
Best use
GHD diagnostic
Status
Investigational
TL;DR
01
A synthetic hexapeptide that stimulates the pituitary to release growth hormone by activating the ghrelin receptor — one of the classic GH-releasing peptides.
02
Its best-validated human use is not as a therapy but as a diagnostic agent: a GHRP-2 stimulation test helps diagnose adult growth-hormone deficiency (used clinically in Japan).
03
It reliably raises GH in people, but there are no trials showing it produces meaningful body-composition, strength, or anti-aging benefits.
04
Like other ghrelin-receptor agonists it also increases appetite and can nudge cortisol and prolactin, and the GH response fades with continued use.
05
It is not an approved therapy for muscle or anti-aging use; consumer supply is research-grade and unregulated.
Human GH release
Proven
robust, dose-dependent
Validated use
GHD diagnosis
stimulation test (Japan)
Therapeutic RCTs
None
no body-comp/anti-aging outcomes
Appetite
Increased
ghrelin-receptor effect
Tolerance
GH response fades
with continued use
Part 01 · How it works
Mechanism.
GHRP-2 mimics ghrelin at the pituitary's growth-hormone-secretagogue receptor, prompting a pulse of growth hormone. That effect is strong and reliable enough that doctors use a single GHRP-2 dose as a diagnostic test — if the pituitary responds, it can make GH. Using it repeatedly as a treatment is a different proposition: the body's GH response tends to blunt over time, and no trials have shown that the GH it releases translates into the muscle or anti-aging results it's marketed for.
It's a reliable 'knock' on the pituitary door that makes it release growth hormone — useful as a one-time test of whether the door works, but knocking daily doesn't obviously build anything, and the door starts answering less.
GHS-R1a agonism
Agonist at the ghrelin/growth-hormone-secretagogue receptor, driving pulsatile GH release.
Diagnostic validation
GHRP-2 stimulation test is an accepted alternative to the insulin tolerance test for diagnosing adult GH deficiency.
Off-target hormones
Less selective than ipamorelin — can modestly raise cortisol and prolactin, and it stimulates appetite.
Tachyphylaxis
Repeated dosing tends to blunt the GH response over time.
Part 02 · Dosing & administration
How it's taken.
Community-reported · unregulatedValues below reflect commonly reported community protocols for GHRP-2. These are anecdotal and unregulated — not clinically validated and not a recommendation. Provided for educational purposes only — this is not medical advice and not instructions for self-administration. Consult your healthcare provider before making any health decision.
Standard dose
100-300 mcg
Subcutaneous injection · 2–3x daily (empty stomach; pre-meal and/or bedtime)
Duration
8–12 week cycle
·
Community "saturation" dose is ~100 mcg; higher doses give diminishing GH return and more side effects.
·
Strongest GH release of the GHRP family but also raises prolactin, ACTH and cortisol — confirmed in humans at 2 mcg/kg IV (Arvat 1999).
·
Diagnostic/stimulation-test use is ~1 mcg/kg as a single dose; there is no FDA-approved therapeutic regimen, so circulating protocols are unregulated.
Need help with reconstitution?
Use the free peptide calculator for dilution, unit conversion, and injection volume.
Part 03 · Safety
Side effects, rare serious events, who shouldn't.
Common
Increased appetite
Ghrelin-receptor effect.
Common
Flushing / head-rush
Transient.
Reported
Injection-site reactions
Anecdotal.
Reported
Serious · rare
Cortisol / prolactin rise
Less selective than ipamorelin; modest elevations possible.
Mild
IGF-1 / glucose effects
Chronic GH elevation carries insulin-resistance and mitogenic cautions; unstudied long-term.
Theoretical
Product-quality risk
Research-grade supply may not match labeled purity/dose.
Source-dependent
Absolute · do not use
×
Active malignancy or history of cancer
×
Pituitary tumor or hypothalamic disorders
×
Diabetic retinopathy
×
Pregnancy or breastfeeding
×
Children under 18 (unless for diagnosed GH deficiency under specialist care)
×
Known hypersensitivity to GHRP-2 or any component
Relative · discuss first
!
Active or prior malignancy — GH/IGF-1 mitogenic caution
!
Pregnancy or breastfeeding — no data
!
Diabetes or impaired glucose tolerance — GH raises insulin resistance
!
Anyone expecting proven therapeutic benefit — only diagnostic/GH-release data exists
Interactions
Insulin
GH secretagogues increase insulin resistance; may require insulin dose adjustment
Major
Oral hypoglycemics
GH elevation may counteract glucose-lowering effects; monitor blood glucose
Moderate
Corticosteroids
Chronic corticosteroid use blunts GH release and may reduce GHRP-2 efficacy
Moderate
Thyroid hormone replacement
GH can increase T4 to T3 conversion; thyroid levels may need reassessment
Moderate
Somatostatin analogs (octreotide)
Directly antagonizes GH release stimulated by GHRP-2
Major
Labs to monitor
IGF-1
Baseline, 4 weeks, then every 3 months
Monitor growth hormone axis stimulation
Fasting Glucose & Insulin
Baseline and monthly
GH can impair insulin sensitivity
Prolactin
Baseline and at 4 weeks
GHRP-2 can elevate prolactin
Cortisol (AM)
Baseline and at 4 weeks
GHRP-2 stimulates cortisol release
CMP (Comprehensive Metabolic Panel)
Baseline and every 3 months
Liver and kidney function
Part 04 · Evidence
How strong is the evidence?
66
Grade B
Grade B, Emerging. GHRP-2 has solid human pharmacology — it reliably releases GH and is validated as a diagnostic — but no therapeutic outcome trials for the muscle/anti-aging uses it is marketed for, plus appetite and tachyphylaxis caveats.
Mechanistic plausibility
Well-characterized ghrelin-receptor GH release.
80
Human evidence
Robust GH-release and diagnostic data; no therapeutic efficacy RCTs.
58
Safety & tolerability
Generally tolerated short-term; appetite increase and mild cortisol/prolactin effects; long-term data limited.
66
Durability
GH response tends to blunt with continued use.
55
Independence
Diagnostic use studied across independent groups.
66
Part 05 · Research log
Every study we cite.
We list each study with its methodology, funding source, and our quality grade. Flagged studies aren't dismissed — they're tagged so you can weigh them.
01
2012
Endocrine Journal Flagged
Arginine and GHRP-2 tests as alternatives to the insulin tolerance test for adult GH deficiency
The GHRP-2 test produced robust GH responses (median peak 28.9 µg/L vs 9.4 for the insulin tolerance test) and was an acceptable diagnostic alternative for adult GH deficiency.
Comparative diagnostic study · n = 71 · Establishes diagnostic value, not therapeutic benefit.
PMID 23079545 ↗
Moderate
Evidence against
What didn't work, and where the evidence is thin.
Every publication is incentivized to tell you a peptide works. We catalogue the null results, failed trials, and mechanism limits we found in the same literature — so you can weigh them against the upside, with your provider.
01
Reliable GH release, but no therapeutic outcome trials
Mechanism limit Endocrine Journal · 2012
GHRP-2's validated human role is diagnostic — provoking a GH pulse to test pituitary function. No controlled trial shows that repeated therapeutic use improves body composition, strength, recovery, or aging outcomes.
What this means: That it releases GH is not in doubt; that doing so repeatedly helps anything is unproven. The marketed use runs ahead of the evidence.
PMID 23079545 ↗
02
Appetite, off-target hormones, and fading response
Mechanism limit class pharmacology · 2012
As a ghrelin-receptor agonist, GHRP-2 increases appetite and can modestly raise cortisol and prolactin; the GH response also tends to blunt with continued dosing (tachyphylaxis).
What this means: The side-effect profile and diminishing returns further undercut the case for chronic use.
PMID 23079545 ↗
Part 06 · Cost & access
Where it's available, at what price.
United States
Not approved (therapy)
No approved therapeutic product; sold as a research chemical. No legal consumer medicine.
Grey-market; unregulated
Japan
Diagnostic use
Used clinically as a GH-stimulation diagnostic agent; not a consumer therapy.
Clinical/diagnostic setting
European Union
Not approved
No approved therapeutic product.
N/A
United Kingdom
Not approved
No approved therapeutic product.
N/A
The Peptide Column takes no affiliate commission from any source. GHRP-2's validated use is diagnostic; it is not an approved therapy for muscle or anti-aging use, and consumer supply is research-grade and unregulated. We link only to clinician-directed care, never to sellers.
Part 07 · Your appointment
Questions to bring.
01
How does GHRP-2 compare to GHRP-6 or ipamorelin for my goals?
02
What baseline labs (IGF-1, GH, cortisol, prolactin) should I have before starting?
03
Will GHRP-2's effect on cortisol and prolactin be a concern for me?
04
What is the optimal timing and dosing protocol for GHRP-2?
05
Should GHRP-2 be combined with a GHRH analog like CJC-1295 for synergy?
06
How long should I cycle GHRP-2, and is there risk of pituitary desensitization?
References
Every citation, numbered.
Citation list. For our editorial read of each study — including bias flags and quality grades — see the Research log above.
- 01. Arginine and GHRP-2 tests as alternatives to the insulin tolerance test for adult GH deficiency · Endocrine Journal, 2012 · PMID 23079545 ↗
- 02. PubMed. GHRP-2 GH-release / diagnostic literature